Robert Naclerio to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Robert Naclerio has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.875
-
Should clinicians use omalizumab for the treatment of nasal polyps? J Allergy Clin Immunol. 2013 Jul; 132(1):247.
Score: 0.308
-
Persistence of Sinonasal Disease Despite Mepolizumab. J Allergy Clin Immunol Pract. 2020 05; 8(5):1550-1555.
Score: 0.123
-
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020 Feb 01; 58(1):10-17.
Score: 0.122
-
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020 01; 75(1):148-157.
Score: 0.120
-
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019 Sep - Oct; 7(7):2447-2449.e2.
Score: 0.115
-
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010 09; 48(3):318-24.
Score: 0.064
-
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 02; 315(5):469-79.
Score: 0.023